We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Survey on the Pharmacy Follow-up of Alli Purchasers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01387243
First Posted: July 4, 2011
Last Update Posted: October 29, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
  Purpose
To assess the feasibility and acceptability of genuine pharmacy follow up of people wishing to lose weight.

Condition Intervention
Overweight Drug: Orlistat

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Survey on the Pharmacy Follow up of Alli Purchasers

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Change in Physical activity [ Time Frame: baseline to 1 year ]

Secondary Outcome Measures:
  • Change in dietary behavior [ Time Frame: baseline to 1 year ]
  • Evaluation of care pathway (e.g., consultation with doctors, use of nutritional information) [ Time Frame: baseline to 1 year ]
  • Satisfaction with management (i.e., results on weight and treatment comfort) [ Time Frame: baseline to 1 year ]

Enrollment: 80
Study Start Date: January 2010
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
60 mg Orlistat
Purchased by consumer
Drug: Orlistat
60 mg

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Consumers purchasing orlistat in a pharmacy setting
Criteria

Inclusion Criteria:

  • Individuals who have been recognized as being eligible for treatment, who have agreed to pharmacy follow up, and have given their informed consent to take part in the survey.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01387243


Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01387243     History of Changes
Other Study ID Numbers: W5350856
First Submitted: March 29, 2010
First Posted: July 4, 2011
Last Update Posted: October 29, 2012
Last Verified: October 2012

Keywords provided by GlaxoSmithKline:
behavior modification
overweight
orlistat

Additional relevant MeSH terms:
Overweight
Body Weight
Signs and Symptoms
Orlistat
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Obesity Agents